-
Zuclopenthixol
- indication:For the management of the manifestations of schizophrenia.
- pharmacologypharmacology:
- mechanism: Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene group. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
- toxicity: Although there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia.
- absorprion:
- halflife: 20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.
- roouteelimination:
- volumedistribution:
- clearance: